Direct Stent, no clinical utility in patients undergoing elective

 Original title: The Independent Value of a Direct Stenting Strategy on Early and Late Clinical Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention. Reference: Gabriel L. Sardi et al. Catheterization and Cardiovascular Interventions 81:949–956 (2013).

 

The use of direct stenting (DS) without pre-stenting dilation has proven to be a safe strategy, especially with the advances that have been achieved in the profile of the new generation devices. In theory, the incidence of peri-procedural myocardial injury and no-reflow phenomenon would be lower given the slightest chance of distal embolization and wall damage compared to pre systematic dilation. In this study, the decision regarding what strategy to use was at the discretion of the operator, so that propensity score was used to match the differences in baseline characteristics of both groups, which left 444 patients in each branch for the final analysis. 

The primary endpoint of the analysis was the extent of myocardial injury peri-procedural according to the elevation of CK-MB. The indicative variables of the use of resources such as procedure time, contrast volume and post dilatation balloons used were significantly higher in pre branch dilatation. The peri-procedural myocardial injury was virtually identical in both groups, (5.3% versus PD SD 5.4%, p = 0.91), as was the incidence of death, myocardial infarction, revascularization or a combination of all (MACE). 

Conclusion: 

In the context of elective angioplasty, a direct stenting strategy reduces procedure time and resource utilization but has no demonstrable clinical benefit at one year. 

Editorial comment: 

The mere fact of diminishing resources, and therefore costs, seems to be reason enough to use direct stenting. Perhaps the most important aspect is correctly judging the injury before starting and choosing a strategy according to the anatomical complexity. These results should not be extended to studying patients with acute coronary syndrome

SOLACI

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...